

| Id | Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial | Target Number Of Patients Agreed? | Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number) | Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number) | Target Date To Recruit Patients Agreed? | Date Agreed to recruit target number of patients | Total Number Of Patients Recruited At The Agreed Target Date | Date That The Trial Closed To Recruitment | Total Number Of Study Participants Recruited | Reason For Closure Of Trial | Comments |
|-------|--|---|--|-----------------------------------|---|---|---|--|--|---|--|-----------------------------|---|
| 47501 | 17/SW/0221 | 232448 | A randomized, partially-blinded, active-controlled, multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy | Range Agreed | 1 | 2 | Date Agreed | 27/06/2019 | 1 | 16/05/2019 | 1 | Withdrawn By Sponsor | Trial closed early by Sponsor |
| 47502 | 16/LO/1509 | 208393 | Narcolepsy Trial Using Once Nightly Sodium Oxybate | Number Agreed | 1 | 1 | Date Agreed | 31/07/2019 | 0 | 20/06/2019 | 0 | Withdrawn By Sponsor | Trial closed early to UK sites due to limited drug supply |
| 47503 | 19/SC/0122 | 259342 | DESTINY PWS - A Study of DCCR in Patients with Prader-Willi Syndrome | Range Agreed | 1 | 3 | Date Agreed | 13/01/2020 | 3 | 31/01/2020 | 3 | Recruitment Finished | |